PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33427061-3 2021 TGFB1-receptor antagonist SD-208 prevents increases of beta6-integrin, TGFB1-SMAD signaling and PDGFB/CTGF expression after IRI, and ameliorates fibrosis (Am J Pathol 174:1291, 2009; Am J Pathol 181:1236, 2012). SD-208 26-32 transforming growth factor beta 1 Homo sapiens 0-5 34013984-7 2021 This inhibitory effect of TGFbeta1 on healthy hematopoiesis was functionally corrobated and could be pharmacologically reverted by SD208, an inhibitor of TGFbeta receptor 1 signaling. SD-208 131-136 transforming growth factor beta 1 Homo sapiens 26-34 33427061-3 2021 TGFB1-receptor antagonist SD-208 prevents increases of beta6-integrin, TGFB1-SMAD signaling and PDGFB/CTGF expression after IRI, and ameliorates fibrosis (Am J Pathol 174:1291, 2009; Am J Pathol 181:1236, 2012). SD-208 26-32 transforming growth factor beta 1 Homo sapiens 71-76 33427061-8 2021 Remarkably, TGFB1 receptor antagonist SD-208 prevented all of these abnormalities excepting increased LPA2. SD-208 38-44 transforming growth factor beta 1 Homo sapiens 12-17 33427061-9 2021 SD208 inhibits only one arm of LPA signaling: LPA2-Galphaq-alphavbeta6-integrin dependent production of active TGFB1 and its receptor-bound downstream effects. SD-208 0-5 transforming growth factor beta 1 Homo sapiens 111-116 33427061-12 2021 SD208 effects may also involve mitigation of injury caused by IRI-induced TGFB1 signaling in endothelial cells and monocytes. SD-208 0-5 transforming growth factor beta 1 Homo sapiens 74-79 27464628-0 2016 [Effects of transforming growth factor beta1 receptor inhibitor SD-208 on human hypertrophic scar]. SD-208 64-70 transforming growth factor beta 1 Homo sapiens 12-44 31442332-8 2019 We also discovered that SD-208 promoted osteoblastic differentiation (and overcame the TGFbeta-induced block in osteoblastogenesis) in myeloma patient bone marrow stromal cells in vitro, comparable to normal donors. SD-208 24-30 transforming growth factor beta 1 Homo sapiens 87-94 32317146-11 2021 Smad signal transduction activation was significantly down-regulated by Bindarit (300 muM) and/or SD208 (1 muM) with TGF-beta1 compared to vehicle control with TGF-beta1. SD-208 98-103 transforming growth factor beta 1 Homo sapiens 117-126 32317146-11 2021 Smad signal transduction activation was significantly down-regulated by Bindarit (300 muM) and/or SD208 (1 muM) with TGF-beta1 compared to vehicle control with TGF-beta1. SD-208 98-103 transforming growth factor beta 1 Homo sapiens 160-169 27464628-1 2016 OBJECTIVE: To investigate the effects of transforming growth factor beta1 (TGF-beta1) receptor inhibitor SD-208 on human hypertrophic scar and its mechanisms. SD-208 105-111 transforming growth factor beta 1 Homo sapiens 41-73 27464628-1 2016 OBJECTIVE: To investigate the effects of transforming growth factor beta1 (TGF-beta1) receptor inhibitor SD-208 on human hypertrophic scar and its mechanisms. SD-208 105-111 transforming growth factor beta 1 Homo sapiens 75-84 27464628-25 2016 CONCLUSIONS: SD-208 has significant inhibition effect on human hypertrophic scars, and the mechanism is correlated to the inhibition of protein expression of endogenous TGF-beta1. SD-208 13-19 transforming growth factor beta 1 Homo sapiens 169-178 27383203-11 2016 Inhibition of TGF-beta-Smad2/3 signaling with SD-208 significantly attenuated the upregulation of miRNA-181b. SD-208 46-52 transforming growth factor beta 1 Homo sapiens 14-22 22985514-4 2012 The TGF-beta 1 receptor kinase inhibitor SD208 enhances microglial proliferation by IL-34 and suppresses the neuroprotective effect of IL-34-treated microglia. SD-208 41-46 transforming growth factor beta 1 Homo sapiens 4-12 25333263-5 2014 SD-208, a TGF-beta receptor 1 specific inhibitor, blocks this TGF-beta induced biology. SD-208 0-6 transforming growth factor beta 1 Homo sapiens 10-18 25333263-5 2014 SD-208, a TGF-beta receptor 1 specific inhibitor, blocks this TGF-beta induced biology. SD-208 0-6 transforming growth factor beta 1 Homo sapiens 62-70 24758301-8 2014 Treatment with a TGF-beta type I receptor kinase inhibitor, SD208, recovered AGE3-induced decreases in osterix (P < .001) and osteocalcin (P < .05) and antagonized the AGE3-induced increase in Runx2 mRNA expression in ST2 cells (P < .001). SD-208 60-65 transforming growth factor beta 1 Homo sapiens 17-25 23725749-7 2013 Moreover, hypoxia induced the phosphorylation of Smad2 and additional treatment with SD-208, an inhibitor of the TGF-beta receptor I kinase, resulted in a dose-dependent downregulation of CD133 and Oct4 in the K562/DOX cells. SD-208 85-91 transforming growth factor beta 1 Homo sapiens 113-121 26523217-0 2015 Down-regulation of miR-135b in colon adenocarcinoma induced by a TGF-beta receptor I kinase inhibitor (SD-208). SD-208 103-109 transforming growth factor beta 1 Homo sapiens 65-73 26523217-12 2015 CONCLUSION: Our data provide novel evidence that anticancer effects of SD-208 (and likely other TGF-beta inhibitors) may be owing to their ability to regulate miRNAs expression. SD-208 71-77 transforming growth factor beta 1 Homo sapiens 96-104 18202349-9 2008 Inhibition of TGF-beta signaling with SD-208 in established MCT-PH resulted in a small but significant improvement in hemodynamic parameters and medial remodeling. SD-208 38-44 transforming growth factor beta 1 Homo sapiens 14-22 22844446-9 2012 SD208, a potent TGFbeta Receptor 1 (TGFbetaR1) kinase inhibitor, can efficiently block TGFbeta1/Smad signaling and attenuate EMT induction. SD-208 0-5 transforming growth factor beta 1 Homo sapiens 87-95 21692070-8 2011 This effect was proportional to the total levels of TGF-beta1 and TGF-beta2 and was blocked by SB-431542 and SD-208, TGF-beta receptor I inhibitors. SD-208 109-115 transforming growth factor beta 1 Homo sapiens 52-61 21692070-8 2011 This effect was proportional to the total levels of TGF-beta1 and TGF-beta2 and was blocked by SB-431542 and SD-208, TGF-beta receptor I inhibitors. SD-208 109-115 transforming growth factor beta 1 Homo sapiens 52-60 21880834-6 2011 Use of a TGF-beta(1)-blocking antibody or blockage of TGF-beta(1) receptor kinase activity with SD208 prevented the CsA- and CsA/SRL-induced increase in TER. SD-208 96-101 transforming growth factor beta 1 Homo sapiens 54-64 21465486-4 2011 Therefore, we assessed the effect of the disruption of TGF-beta/ALK5/Smad signalling by an ALK5 inhibitor (SD-208) in two experimental animal models of intestinal fibrosis: anaerobic bacteria- and trinitrobenzensulphonic acid-induced colitis. SD-208 107-113 transforming growth factor beta 1 Homo sapiens 55-63 22268139-10 2012 A 30-minute pretreatment of SD 208, a TGF-beta receptor-1 kinase inhibitor, prevented Ca(2+) waves from being evoked by TGF-beta. SD-208 28-34 transforming growth factor beta 1 Homo sapiens 38-46 22268139-10 2012 A 30-minute pretreatment of SD 208, a TGF-beta receptor-1 kinase inhibitor, prevented Ca(2+) waves from being evoked by TGF-beta. SD-208 28-34 transforming growth factor beta 1 Homo sapiens 120-128 18202349-5 2008 METHODS: We have used an orally active small-molecule TGF-beta receptor I inhibitor, SD-208, to determine the functional role of this pathway in MCT-PH. SD-208 85-91 transforming growth factor beta 1 Homo sapiens 54-62 18202349-7 2008 Inhibition of TGF-beta signaling with SD-208 significantly attenuated the development of the PH and reduced pulmonary vascular remodeling. SD-208 38-44 transforming growth factor beta 1 Homo sapiens 14-22 15569984-5 2004 Effects of SD-208 on TGF-beta1-induced signaling pathways triggering IL-6 and VEGF transcription in BMSCs were also delineated. SD-208 11-17 transforming growth factor beta 1 Homo sapiens 21-30 16707625-4 2006 We demonstrated that SD-208, but not SD-282, inhibited TGFbeta-induced SMAD signaling, myofibroblast transformation, and collagen gel contraction. SD-208 21-27 transforming growth factor beta 1 Homo sapiens 55-62 15569984-6 2004 RESULTS: SD-208 significantly inhibits not only transcription but also secretion of both IL-6 and VEGF from BMSCs triggered by either TGF-beta1 or adhesion of MM cells to BMSCs. SD-208 9-15 transforming growth factor beta 1 Homo sapiens 134-143 17400764-3 2007 In the present study, SD-208, a 2,4-disubstituted pteridine, ATP-competitive inhibitor of the TGFbeta receptor I kinase (TGFbetaRI), was used to inhibit cellular activities and tumor progression of PANC-1, a human pancreatic tumor line. SD-208 22-28 transforming growth factor beta 1 Homo sapiens 94-101 17400764-7 2007 Using a Boyden chamber motility assay, we demonstrated that SD-208 inhibited TGFbeta-stimulated invasion in vitro. SD-208 60-66 transforming growth factor beta 1 Homo sapiens 77-84 15520202-2 2004 Here we characterize the effects of a novel TGF-beta receptor (TGF-betaR) I kinase inhibitor, SD-208, on the growth and immunogenicity of murine SMA-560 and human LN-308 glioma cells in vitro and the growth of and immune response to intracranial SMA-560 gliomas in syngeneic VM/Dk mice in vivo. SD-208 94-100 transforming growth factor beta 1 Homo sapiens 44-52 15520202-5 2004 Peripheral blood lymphocytes or purified T cells, cocultured with TGF-beta-releasing LN-308 glioma cells in the presence of SD-208, exhibit enhanced lytic activity against LN-308 targets. SD-208 124-130 transforming growth factor beta 1 Homo sapiens 66-74 15520202-7 2004 SD-208 restores the lytic activity of polyclonal natural killer cells against glioma cells in the presence of recombinant TGF-beta or of TGF-beta-containing glioma cell supernatant. SD-208 0-6 transforming growth factor beta 1 Homo sapiens 122-130 15520202-7 2004 SD-208 restores the lytic activity of polyclonal natural killer cells against glioma cells in the presence of recombinant TGF-beta or of TGF-beta-containing glioma cell supernatant. SD-208 0-6 transforming growth factor beta 1 Homo sapiens 137-145 15520202-8 2004 The oral bioavailability of SD-208 was verified by demonstrating the inhibition of TGF-beta-induced Smad phosphorylation in spleen and brain. SD-208 28-34 transforming growth factor beta 1 Homo sapiens 83-91 15520202-12 2004 These data define TGF-beta receptor I kinase inhibitors such as SD-208 as promising novel agents for the treatment of human malignant glioma and other conditions associated with pathological TGF-beta activity. SD-208 64-70 transforming growth factor beta 1 Homo sapiens 18-26 15520202-12 2004 These data define TGF-beta receptor I kinase inhibitors such as SD-208 as promising novel agents for the treatment of human malignant glioma and other conditions associated with pathological TGF-beta activity. SD-208 64-70 transforming growth factor beta 1 Homo sapiens 191-199